Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients
Document Type
Article
Publication Date
1-1-2017
Publication Source (Journal or Book title)
Oncotarget
Recommended Citation
Joshi, A. D., Botham, R. C., Schlein, L. J., Roth, H. S., Mangraviti, A., Borodovsky, A., Tyler, B., Joslyn, S., Looper, J. S., Podell, M., Fan, T. M., Hergenrother, P. J., & Riggins, G. J. (2017). Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients. Oncotarget https://doi.org/10.18632/ONCOTARGET.19085
COinS